AURA logo

Aura Biosciences Inc. (AURA)

$7.15

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AURA

Market cap

$744131259

EPS

-1.61

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.414259

Price on AURA

Previous close

$7.22

Today's open

$7.20

Day's range

$7 - $7.31

52 week range

$4.73 - $9.54

Profile about AURA

CEO

Elisabet de los

Employees

113

Headquarters

Boston, MA

Exchange

NASDAQ Global Market

Shares outstanding

104074302

Issue type

Common Stock

AURA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AURA

OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate

Oxford, UK – 17 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today confirm its manufacturing and supply partnership with Aura Biosciences, Inc. (“Aura”) (NASDAQ: AURA), a biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers. OXB is supporting late-stage development and manufacturing activities for Aura's lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar), as Aura advances the programme through Phase 3 development and prepares for potential future commercial supply. Aura recently announced the partnership and its manufacturing strategy in its Q3 corporate update.

news source

GlobeNewsWire • Nov 17, 2026

news preview

Here's Why You Should Add AURA Stock to Your Portfolio Now

Aura completes phase III enrollment for bel-sar, with pivotal data expected in 2027 and additional ocular cancer programs expanding its growth potential.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 119.6% in Aura Biosciences (AURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar Early choroidal melanoma investor and analyst virtual event planned for December 8, 2026 Expected cash runway into 1H 2029 BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”) a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “During the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development,” said Natalie Holles, Chief Executive Officer of Aura Biosciences.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Aura Biosciences to Participate in Upcoming Investor Conference

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026. Fireside chat at 2:40 p.m.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

Aura Biosciences offers a de-risked, fully funded play on the bel-sar for early choroidal melanoma, with pivotal Phase 3 data expected in 2027. AURA's cash position of $323.8 million as of June 2026 supports operations into 1H 2029, eliminating near-term financing risk ahead of its binary readout. Strategic refocus on ocular oncology, leadership overhaul, and workforce reduction streamline execution and concentrate resources on a largely uncontested market.

news source

Seeking Alpha • Oct 31, 2026

news preview

Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 16, 2026

news preview

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura's new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura's new Chief Operating Officer, and Julie Person, Aura's new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Sep 1, 2026

news preview

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.

news source

Seeking Alpha • Aug 12, 2026

news preview

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.

news source

GlobeNewsWire • Jul 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Aura Biosciences Inc.

Open an M1 investment account to buy and sell Aura Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AURA on M1